Overview

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb